Income Statement
PYXIS ONCOLOGY, INC.
PYXS
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
13.86 | 16.15 | - | - | - |
|
Cost of Revenue
|
2.40 | 0.48 | - | - | - |
|
Gross Profit
|
11.46 | 15.67 | - | - | - |
|
Operating Expenses
|
95.89 | 84.17 | 82.20 | 123.48 | 69.72 |
|
Research & Development
|
73.70 | 58.75 | 49.59 | 86.13 | 51.05 |
|
Selling, General & Administrative
|
22.19 | 25.42 | 32.61 | 37.35 | 18.66 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-84.43 | -68.50 | -82.20 | -123.48 | -69.72 |
|
Non-Operating Income
|
6.19 | 9.97 | 8.41 | 2.76 | -6.03 |
|
Interest Income
|
0.65 | 0.93 | 1.84 | 2.76 | 0.02 |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | 0.50 | -0.23 |
|
Income Before Tax
|
-78.24 | -79.50 | - | - | - |
|
Income Tax Expense
|
1.39 | -2.16 | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-79.62 | -77.33 | -73.79 | -120.72 | -75.98 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-79.92 | -65.51 | -80.27 | -122.77 | -69.07 |
|
Earnings Per Share (Basic)
|
-1.28 | -1.32 | -1.85 | -3.65 | - |
|
Diluted EPS
|
-1.28 | -1.32 | -1.85 | -3.65 | - |
|
Weighted Average Shares
|
62.14 | 58.45 | 39.90 | 33.03 | - |
|
Diluted Weighted Avg Shares
|
62.14 | 58.45 | 39.90 | 33.03 | - |
|
Comprehensive Income
|
-79.74 | -77.22 | -73.73 | - | - |